

(FILE 'HOME' ENTERED AT 13:34:41 ON 05 SEP 2006)

FILE 'USPATFULL' ENTERED AT 13:34:51 ON 05 SEP 2006

L1 71 S CONJUGATED LINOLEIC ACID/TI  
L2 268 S CONJUGATED LINOLEIC ACID/CLM  
L3 146 S CONJUGATED LINOLEIC ACID/AB  
L4 58 S L1 AND L2 AND L3  
L5 34 S L4 AND (TABLET OR CAPSULE)  
L6 2 S L5 AND PHOSPHOLIPID/CLM  
L7 23 S L5 AND PHOSPHOLIPID  
L8 21 S L7 NOT L6  
L9 0 S L8 AND PHOPHOLIPID/AB  
L10 39 S CONJUGATED LINOLEIC ACID (2S) (PHOSPHOLIPID)  
L11 1 S L10 AND L8

=> save all teamp

TEAMP IS NOT A VALID SAVED NAME

Enter the name you wish to use for the saved query,  
answer set, or L-number list. The name must:

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,  
structure, or screen set), /A for an answer  
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):end

=> save all temp

ENTER NAME OR (END):l10721231a/l

L# LIST L1-L11 HAS BEEN SAVED AS 'L10721231A/L'

75% OF LIMIT FOR SAVED L# LISTS REACHED

=>

L11 ANSWER 1 OF 1 USPATFULL on STN  
TI Agent for increasing brown fat, comprising conjugated linoleic acid as active ingredient  
AB There is provided an agent for increasing brown fat, comprising a conjugated linoleic acid as an active ingredient.  
DETD [0011] Forms of the conjugated linoleic acid usable herein include fatty acids, mono-, di-, or triglycerides, sodium salts, potassium salts, calcium salts, phospholipids, and lysophospholipids, and a mixture of two or more of them. Among them, fatty acids, triglycerides, phospholipids, and calcium salts are preferred. Further, derivatives of conjugated linoleic acids, for example, ascorbic acid derivatives and mitomycin C derivatives, may also be used.  
DETD . . . starch, dextrin, gum arabic or the like). The agent for increasing brown fat may be used in the form of tablets, capsules, or liquids.  
CLM What is claimed is:  
1. An agent for increasing brown fat, comprising a conjugated linoleic acid as an active ingredient.  
2. The agent for increasing brown fat according to claim 1, wherein the conjugated linoleic acid is selected from the group consisting of 9,11-octadecadienoic acid, 10,12-octadecadienoic acid, and a mixture of said compounds.  
3. The agent for increasing brown fat according to claim 1, wherein said conjugated linoleic acid is used in the form of a fatty acid, a sodium salt, a potassium salt, a calcium salt, a triglyceride, . . .  
4. A food or a feed having a capability of increasing brown fat, said food or feed comprising the conjugated linoleic acid according to claim 1.  
5. The food or feed according to claim 4, which is in the form of a conjugated linoleic acid-containing fat-and-oil product.

ACCESSION NUMBER: 2002:26926 USPATFULL  
TITLE: Agent for increasing brown fat, comprising conjugated linoleic acid as active ingredient  
INVENTOR(S): Sugano, Michihiro, Kumamoto-shi, JAPAN  
Sakuno, Masanobu, Miyazaki-shi, JAPAN  
Koba, Kazunori, Nagasaki-shi, JAPAN  
Okuyama, Hitoshi, Tokyo-To, JAPAN  
Kasai, Masaaki, Nagoya-shi, JAPAN  
Iwata, Toshio, Tokyo-To, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015771	A1	20020207
	US 6451336	B2	20020917

APPLICATION INFO.: US 2000-560902 A1 20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-122794	19990428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Foley & Lardner, Washington Harbour, 3000 K Street NW, Suite 500, Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	7	

EXEMPLARY CLAIM: 1  
LINE COUNT: 231  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 58 USPATFULL on STN  
AN 2002:22529 USPATFULL  
TI Conjugated linoleic acid powder  
IN Fimreite, Duane, Chicago, IL, UNITED STATES  
PA Natural ASA, Sandvika, NORWAY, N-1337 (U.S. corporation)  
PI US 2002013365 A1 20020131  
US 6756405 B2 20040629  
AI US 2001-836788 A1 20010417 (9)  
PRAI US 2000-198487P 20000418 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1330  
INCL INCLM: 514/552.000  
INCLS: 514/560.000; 514/547.000  
NCL NCLM: 514/560.000; 514/552.000  
NCLS: 424/439.000; 514/546.000; 514/549.000; 514/558.000; 514/547.000  
IC [7]  
ICM A61K031-232  
ICS A61K031-202  
IPCI A61K0031-232 [ICM,7]; A61K0031-21 [ICM,7,C\*]; A61K0031-202  
[ICS,7]; A61K0031-185 [ICS,7,C\*]  
IPCI-2 A61K0031-22 [ICM,7]; A61K0031-20 [ICS,7]; A61K0031-185  
[ICS,7,C\*]; A61K0007-00 [ICS,7]; A61K0031-231 [ICS,7];  
A61K0031-21 [ICS,7,C\*]; A61K0035-78 [ICS,7]  
IPCR A23D0009-02 [I,C\*]; A23D0009-05 [I,A]; A23K0001-16 [I,A];  
A23K0001-16 [I,C\*]; A23K0001-18 [I,A]; A23K0001-18 [I,C\*];  
A23L0001-30 [I,A]; A23L0001-30 [I,C\*]; A61K0031-185 [I,C\*];  
A61K0031-20 [I,A]; A61K0031-21 [I,C\*]; A61K0031-23 [I,A];  
A61K0031-231 [I,A]; C11B0003-00 [I,C\*]; C11B0003-10 [I,A];  
C11B0003-12 [I,A]; C11C0003-00 [I,C\*]; C11C0003-02 [I,A];  
C11C0003-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 14 and (tablet or capsule)  
L5 34 L4 AND (TABLET OR CAPSULE)

=> d 20-30

L5 ANSWER 20 OF 34 USPATFULL on STN  
AN 2002:266471 USPATFULL  
TI Bioactive conjugated linoleic acid  
glycerides and method of use  
IN Bonsignore, Patrick V., UNITED STATES  
Gurin, Michael H., UNITED STATES  
PI US 2002147356 A1 20021010  
US 6608222 B2 20030819  
AI US 2001-1413 A1 20011121 (10)  
PRAI US 2000-252382P 20001121 (60)  
US 2000-250359P 20001201 (60)  
US 2000-254317P 20001211 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1346  
INCL INCLM: 554/121.000  
NCL NCLM: 554/126.000; 554/121.000  
NCLS: 424/442.000; 424/451.000; 426/807.000  
IC [7]  
ICM C11D001-28  
IPCI C11D0001-28 [ICM,7]; C11D0001-02 [ICM,7,C\*]  
IPCI-2 C11C0003-14 [ICM,7]; C11C0003-00 [ICM,7,C\*]  
IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C\*]; A23L0001-30 [I,A];  
A23L0001-30 [I,C\*]; A23L0002-02 [I,A]; A23L0002-02 [I,C\*];  
A23L0002-52 [I,A]; A23L0002-52 [I,C\*]; C11C0003-00 [I,C\*];

C11C0003-02 [I,A]; C11C0003-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 34 USPATFULL on STN  
AN 2002:217238 USPATFULL  
TI **Conjugated linoleic acid in treatment and prophylaxis of diabetes**  
IN Remmereit, Jan, Volda, NORWAY  
Wadstein, Jan, Oslo, NORWAY  
Klaveness, Jo, Oslo, NORWAY  
PA Natural Corporation, Sandvira, NORWAY (non-U.S. corporation)  
PI US 6440931 B1 20020827  
AI US 2000-510059 20000222 (9)  
PRAI US 1999-121232P 19990223 (60)  
DT Utility  
FS GRANTED  
LN.CNT 783  
INCL INCLM: 514/003.000  
INCLS: 514/003.000; 514/002.000; 514/560.000; 514/549.000; 514/558.000;  
426/630.000; 426/002.000; 426/807.000  
NCL NCLM: 514/003.000  
NCLS: 426/002.000; 426/630.000; 426/807.000; 514/002.000; 514/549.000;  
514/558.000; 514/560.000  
IC [7]  
ICM A61K038-28  
IPCI A61K0038-28 [ICM,7]  
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C\*]; A61K0031-155 [I,A];  
A61K0031-155 [I,C\*]; A61K0031-185 [I,C\*]; A61K0031-201 [I,A];  
A61K0031-64 [I,A]; A61K0031-64 [I,C\*]; A61K0031-702 [I,A];  
A61K0031-702 [I,C\*]; A61K0038-28 [I,A]; A61K0038-28 [I,C\*]  
EXF 514/2; 514/3; 514/560; 514/549; 514/558; 426/630; 426/2; 426/807  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 34 USPATFULL on STN  
AN 2002:201689 USPATFULL  
TI **Dietary supplement containing glycerol ester of conjugated linoleic acid and rosemary extract containing carnosic acid**  
IN Krumhar, Kim Carleton, Carlsbad, CA, United States  
PA Metagenics, Inc., San Clemente, CA, United States (U.S. corporation)  
PI US 6432453 B1 20020813  
AI US 2001-775299 20010201 (9)  
PRAI US 2000-228249P 20000826 (60)  
DT Utility  
FS GRANTED  
LN.CNT 409  
INCL INCLM: 424/725.000  
INCLS: 424/439.000  
NCL NCLM: 424/725.000  
NCLS: 424/439.000  
IC [7]  
ICM A61K047-08  
ICS A61K035-78  
IPCI A61K0047-08 [ICM,7]; A61K0035-78 [ICS,7]  
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C\*]  
EXF 514/560; 514/909; 424/725; 424/439  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 34 USPATFULL on STN  
AN 2002:185364 USPATFULL  
TI **Conjugated linoleic acid compositions**  
IN Fimreite, Duane, Chicago, IL, UNITED STATES  
Saebo, Asgeir, Eidsnes, NORWAY  
PA Natual, Sandvika, NORWAY (U.S. corporation)

PI US 2002098274 A1 20020725  
US 6524527 B2 20030225  
AI US 2001-961522 A1 20010924 (9)  
RLI Continuation-in-part of Ser. No. US 1998-132593, filed on 11 Aug 1998,  
PENDING Continuation-in-part of Ser. No. US 1999-270940, filed on 17 Mar  
1999, PENDING Continuation-in-part of Ser. No. US 1998-42767, filed on  
17 Mar 1998, PATENTED Continuation-in-part of Ser. No. US 1998-42538,  
filed on 17 Mar 1998, ABANDONED

DT Utility  
FS APPLICATION

LN.CNT 1960

INCL INCLM: 426/601.000  
INCLS: 424/439.000  
NCL NCLM: 426/648.000; 426/601.000  
NCLS: 554/126.000; 424/439.000

IC [7]  
ICM A23D007-00  
ICS A23D009-00  
IPCI A23D0007-00 [ICM,7]; A23D0009-00 [ICS,7]  
IPCI-2 A23L0001-30 [ICM,7]  
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C\*]; A61K0031-185 [I,C\*];  
A61K0031-201 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 34 USPATFULL on STN

AN 2002:157826 USPATFULL

TI Isomer enriched conjugated linoleic acid  
compositions

IN Jerome, Daria, Owatonna, MN, UNITED STATES  
Skarie, Carl, Detroit Lakes, MN, UNITED STATES

PI US 2002082436 A1 20020627  
US 6696584 B2 20040224

AI US 2001-23598 A1 20011218 (10)

RLI Continuation of Ser. No. US 2001-789583, filed on 22 Feb 2001, PENDING  
Continuation of Ser. No. US 1999-438101, filed on 10 Nov 1999, PATENTED  
Continuation of Ser. No. US 1998-72422, filed on 4 May 1998, PATENTED

DT Utility  
FS APPLICATION

LN.CNT 577

INCL INCLM: 554/221.000

NCL NCLM: 554/224.000; 554/221.000  
NCLS: 424/451.000; 424/648.000; 424/807.000; 554/223.000; 554/227.000

IC [7]  
ICM C11B001-00  
ICS C07C053-00; C07C057-00  
IPCI C11B0001-00 [ICM,7]; C07C0053-00 [ICS,7]; C07C0057-00 [ICS,7]  
IPCI-2 C07C0057-00 [ICM,7]  
IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C\*]; A23L0001-30 [I,A];  
A23L0001-30 [I,C\*]; A61K0031-185 [I,C\*]; A61K0031-202 [I,A];  
C11B0003-00 [I,A]; C11B0003-00 [I,C\*]; C11C0001-00 [I,C\*];  
C11C0001-02 [I,A]; C11C0003-00 [I,C\*]; C11C0003-02 [I,A];  
C11C0003-10 [I,A]; C11C0003-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 34 USPATFULL on STN

AN 2002:152815 USPATFULL

TI Conjugated linoleic acid compositions and  
methods of making same

IN Saebo, Asgeir, Oersta, NORWAY  
Skarie, Carl, Detroit Lakes, MN, United States  
Jerome, Daria, Owatonna, MN, United States  
Haroldsson, Gudmunder, Reykjavik, ICELAND

PA Conlinco, Inc., Detroit Lakes, MN, United States (U.S. corporation)  
PI US 6410761 B1 20020625

L5 ANSWER 19 OF 34 USPATFULL on STN  
TI **Conjugated linoleic acid compositions and methods of making same**  
IN Saebo, Asgeir, Oersta, NORWAY  
Skarie, Carl, Detroit Lakes, MN, UNITED STATES  
Jerome, Daria, Owatonna, MN, UNITED STATES  
Haroldsson, Gudmundur, Reykjavik, ICELAND  
PI US 2002169332 A1 20021114  
US 6610868 B2 20030826  
PI US 2002169332 A1 20021114  
US 6610868 B2 20030826  
AB Novel compositions containing **conjugated linoleic acids** are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.

L5 ANSWER 20 OF 34 USPATFULL on STN  
TI **Bioactive conjugated linoleic acid glycerides and method of use**  
IN Bonsignore, Patrick V., UNITED STATES  
Gurin, Michael H., UNITED STATES  
PI US 2002147356 A1 20021010  
US 6608222 B2 20030819  
PI US 2002147356 A1 20021010  
US 6608222 B2 20030819  
AB A composition and method for supplementing feed, nutrition and diet systems with bioactive glycerides of **conjugated linoleic acid** comprised of a synergistic blend of conjugated linoleic bioactive isomers acid in mono-, di-, and/or triglyceride form. The composition comprises (A) bioactive glycerides of **conjugated linoleic acid** comprised of a synergistic blend of conjugated linoleic bioactive isomers acid in mono-, di- and/or triglyceride form, (B) a carrier medium, and (C) a delivery system as a dietary supplement. The composition provides an effective increase in nutritional, therapeutic, and pharmacological properties in nutrition and diet systems.

L5 ANSWER 21 OF 34 USPATFULL on STN  
TI **Conjugated linoleic acid in treatment and prophylaxis of diabetes**  
IN Remmereit, Jan, Volda, NORWAY  
Wadstein, Jan, Oslo, NORWAY  
Klaveness, Jo, Oslo, NORWAY  
PI US 6440931 B1 20020827  
PI US 6440931 B1 20020827  
AB This invention provides method of treatment and prophylaxis of both insulin (Type I) and non-insulin dependent (type II) diabetes mellitus, by administration of **conjugated linoleic acid** (CLA) in the form of pure isomers, selected isomer mixtures or non-selected isomer mixtures. The **conjugated linoleic acids** may be administered alone, or in combination with other diabetes therapeutic regimes.

L5 ANSWER 22 OF 34 USPATFULL on STN  
TI **Dietary supplement containing glycerol ester of conjugated linoleic acid and rosemary extract containing carnosic acid**  
IN Krumhar, Kim Carleton, Carlsbad, CA, United States  
PI US 6432453 B1 20020813  
PI US 6432453 B1 20020813  
AB A composition containing a stabilized form of **conjugated linoleic acid** is described. The **conjugated**

AI US 1999-270940 19990317 (9)  
RLI Continuation-in-part of Ser. No. US 1998-132593, filed on 11 Aug 1998  
Continuation-in-part of Ser. No. US 1998-160416, filed on 25 Sep 1998  
Continuation-in-part of Ser. No. US 1998-42538, filed on 17 Mar 1998,  
now abandoned Continuation-in-part of Ser. No. US 1998-42767, filed on  
17 Mar 1998, now patented, Pat. No. US 6015833  
DT Utility  
FS GRANTED  
LN.CNT 1333  
INCL INCLM: 554/126.000  
INCLS: 554/167.000; 554/168.000; 554/173.000  
NCL NCLM: 554/126.000  
NCLS: 554/167.000; 554/168.000; 554/173.000  
IC [7]  
ICM C11C003-00  
IPCI C11C0003-00 [ICM, 7]  
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C\*]; A61K0031-185 [I,C\*];  
A61K0031-201 [I,A]; A61K0047-48 [I,A]; A61K0047-48 [I,C\*]  
EXF 554/126; 554/156; 554/157; 554/173  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 34 USPATFULL on STN  
AN 2002:55070 USPATFULL  
TI Methods of using isomer enriched conjugated linoleic  
acid compositions  
IN Saebo, Asgeir, Oersta, NORWAY  
Skarie, Carl, Detroit Lakes, MN, UNITED STATES  
Jerome, Daria, Owatonna, MN, UNITED STATES  
PI US 2002032233 A1 20020314  
US 7094420 B2 20060822  
AI US 2001-949458 A1 20010907 (9)  
RLI Continuation of Ser. No. US 1998-72421, filed on 4 May 1998, GRANTED,  
Pat. No. US 6214372 Continuation-in-part of Ser. No. US 1998-72422,  
filed on 4 May 1998, GRANTED, Pat. No. US 6060514 Continuation-in-part  
of Ser. No. US 1999-271021, filed on 17 Mar 1999, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 929  
INCL INCLM: 514/549.000  
INCLS: 514/560.000  
NCL NCLM: 424/439.000  
NCLS: 424/400.000  
IC [7]  
ICM A61K031-201  
ICS A61K031-22  
IPCI A61K0031-201 [ICM, 7]; A61K0031-185 [ICM, 7,C\*]; A61K0031-22  
[ICS, 7]; A61K0031-21 [ICS, 7,C\*]  
IPCI-2 A61K0047-00 [I,A]; A61K0009-00 [I,A]  
IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C\*]; A23L0001-30 [I,A];  
A23L0001-30 [I,C\*]; C11B0003-00 [I,A]; C11B0003-00 [I,C\*];  
C11C0001-00 [I,C\*]; C11C0001-02 [I,A]; C11C0003-00 [I,C\*];  
C11C0003-02 [I,A]; C11C0003-10 [I,A]; C11C0003-14 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

linoleic acid is reacted with glycerol to form an ester, which is much more resistant to oxidation than the acid form of the conjugated linoleic acid. The composition can additionally contain antioxidants, such as rosemary leaf extract, tocopherols, chelating agents, ascorbic acid, the like. The composition can also contain a fatty acid and/or glycerol ingredient. A method for supplementing an individual's diet is also described.

L5 ANSWER 23 OF 34 USPATFULL on STN  
TI Conjugated linoleic acid compositions  
IN Fimreite, Duane, Chicago, IL, UNITED STATES  
Saebo, Asgeir, Eidsnes, NORWAY  
PI US 2002098274 A1 20020725  
US 6524527 B2 20030225  
PI US 2002098274 A1 20020725  
US 6524527 B2 20030225  
AB Novel compositions containing conjugated linoleic acids are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products. In addition, the inventions provides compositions that are prepared according to a novel method that controls oxidation of CLA into volatile organic compounds as well as containing metal oxidant chelators to control oxidation during storage.

L5 ANSWER 24 OF 34 USPATFULL on STN  
TI Isomer enriched conjugated linoleic acid compositions  
IN Jerome, Daria, Owatonna, MN, UNITED STATES  
Skarie, Carl, Detroit Lakes, MN, UNITED STATES  
PI US 2002082436 A1 20020627  
US 6696584 B2 20040224  
PI US 2002082436 A1 20020627  
US 6696584 B2 20040224  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 25 OF 34 USPATFULL on STN  
TI Conjugated linoleic acid compositions and methods of making same  
IN Saebo, Asgeir, Oersta, NORWAY  
Skarie, Carl, Detroit Lakes, MN, United States  
Jerome, Daria, Owatonna, MN, United States  
Haroldsson, Gudmunder, Reykjavik, ICELAND  
PI US 6410761 B1 20020625  
PI US 6410761 B1 20020625  
AB Novel compositions containing conjugated linoleic acids are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.

L5 ANSWER 26 OF 34 USPATFULL on STN  
TI Methods of using isomer enriched conjugated linoleic acid compositions  
IN Saebo, Asgeir, Oersta, NORWAY  
Skarie, Carl, Detroit Lakes, MN, UNITED STATES  
Jerome, Daria, Owatonna, MN, UNITED STATES  
PI US 2002032233 A1 20020314  
US 7094420 B2 20060822

PI US 2002032233 A1 20020314  
US 7094420 B2 20060822  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 27 OF 34 USPATFULL on STN  
TI Agent for increasing brown fat, comprising conjugated linoleic acid as active ingredient

IN Sugano, Michihiro, Kumamoto-shi, JAPAN  
Sakuno, Masanobu, Miyazaki-shi, JAPAN  
Koba, Kazunori, Nagasaki-shi, JAPAN  
Okuyama, Hitoshi, Tokyo-To, JAPAN  
Kasai, Masaaki, Nagoya-shi, JAPAN  
Iwata, Toshio, Tokyo-To, JAPAN

PI US 2002015771 A1 20020207  
US 6451336 B2 20020917

PI US 2002015771 A1 20020207  
US 6451336 B2 20020917

AB There is provided an agent for increasing brown fat, comprising a conjugated linoleic acid as an active ingredient.

L5 ANSWER 28 OF 34 USPATFULL on STN

TI Conjugated linoleic acid powder  
IN Fimreite, Duane, Chicago, IL, UNITED STATES

PI US 2002013365 A1 20020131  
US 6756405 B2 20040629

PI US 2002013365 A1 20020131  
US 6756405 B2 20040629

AB A powder containing a high amount of conjugated linoleic acid or other oil is provided. The powder contains either triglycerides containing CLA, free fatty acids of CLA, or alkylesters of CLA, or another desired oil. The powder is free flowing and has good organoleptic properties. The powder may be used as a dietary supplement or combined with foodstuffs to form a food product suitable for consumption by animals or humans.

L5 ANSWER 29 OF 34 USPATFULL on STN

TI Isomer enriched conjugated linoleic acid compositions

IN Saebo, Asgeir, Oersta, Norway  
Skarie, Carl, Detroit Lakes, MN, United States  
Jerome, Daria, Owatonna, MN, United States

PI US 2001025113 A1 20010927  
US 63333353 B2 20011225

PI US 2001025113 A1 20010927  
US 63333353 B2 20011225

AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 30 OF 34 USPATFULL on STN

TI Isomer enriched conjugated linoleic acid compositions

IN Jerome, Daria, Owatonna, MN, United States  
Skarie, Carl, Detroit Lakes, MN, United States

PI US 6242621 B1 20010605

PI US 6242621 B1 20010605  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 31 OF 34 USPATFULL on STN  
TI Isomer enriched conjugated linoleic acid compositions  
IN Saebo, Asgeir, Oersta, Norway  
Skarie, Carl, Detroit Lakes, MN, United States  
Jerome, Daria, Owatonna, MN, United States  
PI US 6225486 B1 20010501  
PI US 6225486 B1 20010501  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 32 OF 34 USPATFULL on STN  
TI Method of using isomer enriched conjugated linoleic acid compositions  
IN Jerome, Daria, Detroit Lakes, MN, United States  
Skarie, Carl, Detroit Lakes, MN, United States  
PI US 6214372 B1 20010410  
PI US 6214372 B1 20010410  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 33 OF 34 USPATFULL on STN  
TI Use of conjugated linoleic acids  
IN Vanderhoek, Jack Y., Bethesda, MD, United States  
PI US 6077525 20000620  
PI US 6077525 20000620  
AB The use of conjugated linoleic acid to inhibit cyclooxygenase-catalyzed conversion of arachidonic acid, thromboxane formation and platelet aggregation.

L5 ANSWER 34 OF 34 USPATFULL on STN  
TI Isomer enriched conjugated linoleic acid compositions  
IN Jerome, Daria, Detroit Lakes, MN, United States  
Skarie, Carl, Detroit Lakes, MN, United States  
PI US 6060514 20000509  
PI US 6060514 20000509  
AB Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.